This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nektar Therapeutics Inc (NKTR)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 200.71M 148.92M 81.19M 71.48M
Cost of Sales 15.61M 24.23M 15.92M 6.94M
Gross Operating Profit 185.10M 124.69M 65.27M 64.54M
Selling, General, and Administrative Expenses 40.92M 40.53M 41.61M 46.76M
Research & Development 147.73M 190.01M 148.68M 126.77M
Operating Income before D & A (EBITDA) -3.56M -105.86M -125.02M -108.99M
Depreciation & Amortization 12.93M 14.28M 14.51M 14.95M
Interest Income 0.00 732.00K 2.31M 2.24M
Other Income - Net 814.00K 392.00K 983.00K -1.04M
Special Income / Charges 0.00 0.00 -1.68M 0.00
Total Income Before Interest Expenses (EBIT) -15.67M -119.01M -137.90M -122.74M
Interest Expense 38.76M 40.76M 33.55M 10.22M
Pre-Tax Income -54.43M -159.77M -171.45M -132.96M
Income Taxes -512.00K 2.25M 406.00K 1.02M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -53.92M -162.01M -171.85M -133.98M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -53.92M -162.01M -171.85M -133.98M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -53.92M -162.01M -171.85M -133.98M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-53.92M -162.01M -170.18M -133.98M
Preferred Dividends
Net Income Available To Common -53.92M -162.01M -171.85M -133.98M
Basic EPS from Continuing Ops. -0.42 -1.40 -1.50 -1.19
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -0.42 -1.40 -1.50 -1.19
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -0.42 -1.40 -1.50 -1.19
Basic Normalized Net Income/Share -0.42 -1.40 -1.48 -1.19
EPS fr Continuing Ops. -0.42 -1.40 -1.50 -1.19
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -0.42 -1.40 -1.50 -1.19
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -0.42 -1.40 -1.50 -1.19
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-0.42 -1.40 -1.48 -1.19
Dividends Paid per Share 0.00 0.00 0.00 0.00
NKTR News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

NKTR Nektar Therapeutics Inc

Chart of NKTR

Analysts Ratings for NKTR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 7 6 6 7
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
GET NKTR ANALYST REPORT

NKTR Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs